McKesson Corporation (NYSE: MCK), a Florida-based pharmaceutical distributor, has agreed to acquire a controlling interest (70%) in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures).
Don’t miss any content from Distribution Strategy Group. Join our list.
Core Ventures is a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS).
FCS has more than 250 physicians and 280 advanced practice providers with nearly 100 locations in Florida.
FCS physicians will continue to hold a minority interest in Core Ventures.
Following the close of the $2.49 billion cash transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within McKesson’s U.S. Pharmaceutical segment.
FCS will join McKesson’s The Oncology Network, but will remain independently owned.
